Upadacitinib (Rinvoq)

2022 Canadian Journal of Health Technologies  
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses upadacitinib (Rinvoq) oral extended-release tablets, 15 mg and 30 mg. Indication: For the treatment of
more » ... s and adolescents 12 years of age and older with refractory, moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., a steroid or biologic), or when the use of such therapies is inadvisable. Upadacitinib (Rinvoq) can be used with or without topical corticosteroids.
doi:10.51731/cjht.2022.480 fatcat:u7hrdq4qcvahvfq7zehgirsx2e